AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01096901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight loss
Description: Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
Study NCT02300532 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03253029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pure Encapsulations Branched Chain Amino Acid powder
Study NCT03253029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control group (no BCAAs provided)
Study NCT01755013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
Study NCT04258722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation Personnel
Description: Type of resuscitation team
Study NCT05493436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MII pH-meter
Description: using multichannel impedance pH-meter
Study NCT03926780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: 38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
Study NCT03926780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Sodium
Description: 38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
Study NCT03786276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-WMR-Only
Description: Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
Study NCT03786276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-only
Description: Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
Study NCT03786276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active VR-WMR
Description: Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
Study NCT03826992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
Study NCT03826992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days
Study NCT03187210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
Study NCT03187210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BeEAM Regimen
Description: standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
Study NCT03187210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM Regimen
Description: standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
Study NCT02956031 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Cervical specimen obtained using speculum examination and cervical collection bush.
Study NCT02956031 — intervention group
Intervention type: OTHER
Intervention: Colposcopy
Description: Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
Study NCT02956031 — intervention group
Intervention type: PROCEDURE
Intervention: LLETZ
Description: The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
Study NCT03073369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol 50000 UNT
Description: Oral Ergocalciferol 50000 IU once daily for 6 weeks
Study NCT03073369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo - one capsule once daily for 6 weeks
Study NCT02469701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab and ablation
Study NCT04002583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer assisted ambulatory electroencephalogram
Description: A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
Study NCT02515799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacholiquine
Description: Inhaled Tacholiquine ®1% - 5ml
Study NCT02515799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study NCT03694769 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: One-hour interview with researcher
Study NCT03694769 — intervention group
Intervention type: OTHER
Intervention: Drop attack diary
Description: Diary of any drop attacks experienced within an 8 week period
Study NCT02151916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental care, AG, MI & fluoride varnish
Description: Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
Study NCT02151916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed intervention
Description: Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
Study NCT00479570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00446687
Description: Single 200mg dose
Study NCT00479570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00118638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa - 2.25 mcg/kg
Description: Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
Study NCT00118638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa - 500mcg
Description: Darbepoetin alfa 500mcg Q3W dosing / placebo QW
Study NCT02397915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF nasal spray
Description: FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
Study NCT02397915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF nasal spray
Description: MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
Study NCT04800484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tall Soft
Description: Tall heel wedge made of soft foam
Study NCT04800484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tall Firm
Description: Tall heel wedge made of firm foam
Study NCT04800484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam
Study NCT04258722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resuscitation Personnel
Description: Type of resuscitation team
Study NCT01995032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg metformin and 7.5 g L-citrulline daily p.o.
Study NCT02064049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
Study NCT02525484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
Study NCT02033629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ce 1 ng/ml
Description: TCI Remifentanil Ce 1 ng/ml
Study NCT02033629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ce 2 ng/ml
Description: TCI Remifentanil Ce 2 ng/ml
Study NCT02033629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ce 3 ng/ml
Description: TCI Remifentanil Ce 3 ng/ml
Study NCT03162744 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post-suicidal crisis interview
Description: Protective factor exploration during post-suicidal crisis interview
Study NCT03889340 — intervention group
Intervention type: DEVICE
Intervention: IQool
Description: Subjects will undergo hypothermia therapy with the IQool system
Study NCT03143153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03143153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT03143153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT03143153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT03143153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT03143153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT01521923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol + Methotrexate (MTX)
Description: Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week.
Study NCT04800484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam
Study NCT01521923 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Methotrexate (MTX)
Description: 1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week.
Study NCT04103151 — intervention group
Intervention type: DEVICE
Intervention: Single lead ECG
Description: Heart Rate Variability will be monitored using a single lead electrocardiogram
Study NCT03625778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
Study NCT03625778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously daily according to the Placebo cohorts.
Study NCT02985918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
Study NCT02985918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
Study NCT03053440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGB-3111
Description: 160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Study NCT03053440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Study NCT03531164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kAYAK ERGOMETER GROUP
Description: Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
Study NCT03531164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
Study NCT03782259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
Study NCT03782259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02045888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRCs prepared by investigational Celution Device
Description: ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
Study NCT02045888 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is visually matched solution
Study NCT04300205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity LED light device
Description: Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
Study NCT04300205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham LED light device
Description: Participants have the light treatment moved off their wound after masking
Study NCT01208324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estrogen patch
Description: 150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
Study NCT01208324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: 31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
Study NCT01208324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: placebo
Study NCT01995032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02760069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled isopropyl alcohol
Description: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Study NCT02760069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol
Description: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Study NCT02760069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ondansetron
Description: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
Study NCT02760069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled normal saline
Description: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
Study NCT02760069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
Study NCT01675141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
Study NCT04363723 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
Study NCT01563952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
Study NCT01208324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
Study NCT01208324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
Study NCT03637257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Guedel airway
Description: Monitoring of breathing
Study NCT03966209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001(PD-1 inhibitor)
Description: 240mg I.V. Q3W
Study NCT02501967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMET
Description: The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
Study NCT00570778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol/glycopyrrolate
Description: Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
Study NCT00570778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indacaterol
Description: Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Study NCT00570778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Study NCT03650413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered based on disease status, as described in the protocol.
Study NCT03379948 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: blood culture to diagnose blood stream infection
Study NCT02014506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/M2 once daily IV on days -7 to -2
Study NCT02014506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV on day -3 and -2